A recent study by Barrio et al. identified somatic PSMB5 substitutions in an MM patient treated with bortezomib, suggesting that resistance acquired through PSMB5 point mutations is clinically relevant [21]. The gene discussed is PSMB5; the disease is Miyoshi myopathy.